Israeli researchers have made a significant discovery regarding the SARS-CoV-2 virus, revealing that its nucleocapsid protein (NP) can inadvertently trigger the immune system to attack healthy cells. A team from the Hebrew University of Jerusalem found that this protein, which typically packages the virus’s genetic material within infected cells, can migrate to adjacent uninfected cells. Here, NP is mistakenly recognized by the immune system as a pathogen, leading to the production of anti-NP antibodies. These antibodies mark healthy cells for destruction, instigating an immune response that can result in inflammation and tissue damage. This mechanism is believed to contribute to severe symptoms of COVID-19 and may play a role in persistent conditions known as long COVID.
In an encouraging development, the study also noted that enoxaparin-a widely used blood thinner-acts as a blocker for NP interaction with healthy cells. This finding suggests potential therapeutic avenues for mitigating immune-related complications associated with COVID-19 and other viral illnesses. The researchers assert that such insights could pave the way for new treatments aimed at enhancing patient outcomes during viral infections.
Meanwhile, in a separate development, a new COVID-19 variant dubbed NB.1.8.1 is raising alarms as it spreads rapidly across various regions worldwide. First detected in January 2025, this variant, classified within the Omicron family, has been reported in several countries, including India, the United States, the United Kingdom, Australia, China, the Maldives, and Egypt. The World Health Organization (WHO) has designated NB.1.8.1 as a "Variant Under Monitoring," indicating that its swift spread necessitates attention but does not currently pose a major threat on a global scale.
These advancements in understanding both the immune response to SARS-CoV-2 and the emergence of new variants underline the ongoing challenges posed by the virus. As researchers continue to explore ways to combat COVID-19 and its variants, these findings hold promise for improving treatment strategies and enhancing public health responses.
In summary, the interaction between the SARS-CoV-2 nucleocapsid protein and healthy cells highlights a critical aspect of the immune response that can lead to severe COVID-19 symptoms. The potential application of enoxaparin presents a promising avenue for therapeutic intervention. As the world navigates the complexities of COVID-19 variants like NB.1.8.1, ongoing research and vigilance remain essential in the fight against this pandemic.
This evolving landscape of viral behavior and immune response will be crucial as healthcare systems worldwide aim to adapt and respond effectively in the face of emerging challenges.
Categories: Health, COVID-19
Tags: SARS-CoV-2, Nucleocapsid Protein, COVID-19 Variants, Enoxaparin, Immune Response, Long COVID, WHO
Original Source: https://www.newsonair.gov.in/covid-19-virus-protein-triggers-immune-attack-on-healthy-cells-study/
Category :
Tags:
Publish Date: 2025-06-11 13:06:00
